[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Kalender M, Sevinc A, Tutar E, Sirikci A, Camci C: Effect of sunitinib on metastatic gastrointestinal stromal tumor in patients with neurofibromatosis type 1: a case report. World J Gastroenterol; 2007 May 14;13(18):2629-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of sunitinib on metastatic gastrointestinal stromal tumor in patients with neurofibromatosis type 1: a case report.
  • Patients with neurofibromatosis NF type 1 have an increased risk of developing GI tumors including rare types such as GIST.
  • The patient was diagnosed with NF four years ago and his medical history revealed that he was hospitalized 5 times with a provisional diagnosis of massive lower gastrointestinal bleeding.
  • Computerized tomography showed peritoneal implants three months later.
  • However, control computerized tomography revealed liver and omental metastasis.
  • Despite high dosage, the progression of the metastatic lesions continued in the liver and omentum.
  • The patient started oral sunitinib malate (Sutent) Pfizer Inc, New York, NY, USA) 50 mg per day for 4 consecutive weeks, followed by 2 wk off per treatment cycle.
  • The metastatic lesions in the liver and omentum were decreased in size after four courses, suggesting that sunitinib is also an effective treatment modality for metastatic GIST in NF patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Indoles / therapeutic use. Liver Neoplasms / drug therapy. Neurofibromatosis 1 / complications. Pyrroles / therapeutic use
  • [MeSH-minor] Humans. Male. Middle Aged. Omentum / pathology

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2000 Nov;97(11):1385-90 [11215189.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):625-41 [12717247.001]
  • [Cites] Curr Opin Neurol. 2004 Apr;17(2):101-5 [15021234.001]
  • [Cites] Z Gastroenterol. 2004 Oct;42(10):1183-7 [15508060.001]
  • [Cites] Histopathology. 1991 Jul;19(1):1-11 [1916682.001]
  • [Cites] Am J Surg Pathol. 1993 Jul;17(7):706-14 [8317611.001]
  • [Cites] Ultrastruct Pathol. 1993 May-Aug;17(3-4):307-14 [8266596.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1998 Sep;10(9):791-4 [9831275.001]
  • [Cites] AJR Am J Roentgenol. 2004 Dec;183(6):1629-36 [15547202.001]
  • [Cites] AJR Am J Roentgenol. 2004 Dec;183(6):1844-6 [15547245.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):90-6 [16330947.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):705-12 [11034250.001]
  • (PMID = 17552016.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib
  • [Other-IDs] NLM/ PMC4146829
  •  go-up   go-down


2. Shih KK, Zhou QC, Aghajanian C, Huh J, Soslow RA, Morgan JC, Iasonos A, Chi DS, Barakat RR, Abu-Rustum NR: Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors. Gynecol Oncol; 2010 Nov;119(2):270-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors.
  • OBJECTIVE: The objective of this study was to evaluate patterns of recurrence and prognostic factors as well as the role of adjuvant chemotherapy in stage II-IV ovarian SBT.
  • Progression-free survival (PFS) was defined as the time of diagnosis to time of recurrence/death or last follow-up.
  • The site of metastasis was pelvis in 15 patients (19%), omentum in 29 patients (36%), isolated lymph nodes in 2 patients (2.5%), lung in 1 patient (1%), axilla in 1 patient (1%), and multiple sites in 32 patients (40%).
  • With a median follow-up of 4.8 years, 17 patients (21%) developed recurrent disease.
  • Only patients with metastasis to the omentum or multiple sites developed recurrent disease.
  • Of the 65 stage III/IV patients, 17 patients (26%) received adjuvant chemotherapy following diagnosis.
  • The 3-year progression-free survival (PFS) was 89.9% (95% CI, 77.3-95.7) for patients who did not receive adjuvant chemotherapy compared with 70.6% (95% CI, 43.1-86.6) for patients who received adjuvant chemotherapy.
  • It is unclear from these data if adjuvant chemotherapy influenced PFS.
  • [MeSH-major] Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20719369.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS774350; NLM/ PMC4843122
  •  go-up   go-down


3. Khan S, Taylor JL, Rinker-Schaeffer CW: Disrupting ovarian cancer metastatic colonization: insights from metastasis suppressor studies. J Oncol; 2010;2010:286925
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disrupting ovarian cancer metastatic colonization: insights from metastasis suppressor studies.
  • Ovarian cancer affects approximately 25,000 women in the United States each year and remains one of the most lethal female malignancies.
  • A standard approach to therapy is surgical cytoreduction, after which the remaining microscopic residual disease is treated with chemotherapy.
  • The vast majority of patients have disease recurrence, underscoring the crucial need for approaches to control the regrowth, or colonization, of tissues after local treatment.
  • Improved therapies require mechanistic information about the process of metastatic colonization, the final step in metastasis, in which cancer cells undergo progressive growth at secondary sites.
  • Studies of metastasis suppressors are providing insights into events controlling metastatic colonization.
  • This paper reviews our laboratory's approach to the identification, characterization, and functional testing of the JNKK1/MKK4 metastasis suppressor in ovarian cancer metastatic colonization.
  • Specifically, we demonstrate that interaction of ovarian caner cells with the omental microenvironment activates JNKK1/MKK4 resulting in decreased proliferation without affecting apoptosis.
  • The potential role of the omental microenvironment, specifically milky spot structures, is also described.
  • It is our goal to provide this work as a usable paradigm that will enable others to study metastasis suppressors in clinical and experimental ovarian cancer metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5400-2 [1394145.001]
  • [Cites] Res Immunol. 1992 May;143(4):401-9 [1518954.001]
  • [Cites] Arch Histol Cytol. 1990;53 Suppl:165-77 [2252628.001]
  • [Cites] Semin Oncol. 1989 Apr;16(2):91-105 [2652316.001]
  • [Cites] J Natl Cancer Inst. 1989 May 3;81(9):648-9 [2709420.001]
  • [Cites] Science. 1984 Jun 1;224(4652):998-1001 [6719130.001]
  • [Cites] Anat Rec. 1995 Feb;241(2):163-74 [7710133.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):687-92 [8425204.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):804-6 [8657286.001]
  • [Cites] Science. 1998 Apr 24;280(5363):599-602 [9554853.001]
  • [Cites] Biochem Soc Symp. 1999;64:1-12 [10207617.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5483-7 [10554023.001]
  • [Cites] Physiol Rev. 2001 Apr;81(2):807-69 [11274345.001]
  • [Cites] Respirology. 2002 Sep;7(3):171-91 [12153683.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6717-23 [12438272.001]
  • [Cites] Cancer Lett. 2003 Jul 30;198(1):1-20 [12893425.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jan;36(1):9-16 [14592528.001]
  • [Cites] Cell Cycle. 2005 Jan;4(1):57-62 [15611649.001]
  • [Cites] Anat Embryol (Berl). 2005 Feb;209(3):251-61 [15662530.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2264-70 [16489030.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3882-9 [16818682.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1739-52 [17071597.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):67-73 [18049862.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2166-75 [18381422.001]
  • [Cites] Clin Exp Metastasis. 2009;26(1):67-76 [18516689.001]
  • [Cites] Cancer Lett. 2008 Dec 8;272(1):12-22 [18572308.001]
  • [Cites] Cancer Microenviron. 2008 Dec;1(1):1-11 [19308680.001]
  • (PMID = 20300552.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009566
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2838371
  •  go-up   go-down


Advertisement
4. Huang KH, Chung SD, Huang SY, Chueh SC, Chen CA, Chen J: Coexistence of ovarian cancer and renal cell carcinoma. J Formos Med Assoc; 2007 Mar;106(3 Suppl):S15-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of ovarian cancer and renal cell carcinoma.
  • Coexistence of ovarian cancer and renal cell carcinoma (RCC) is extremely rare.
  • Computed tomography scan showed a right cystic adnexal mass measuring 10 x 10 cm, and another tumor measuring 3 x 2 cm at the right kidney.
  • Pathologic examination revealed right ovarian clear-cell carcinoma with peritoneal, omental, and fallopian tube metastasis, and conventional clear-cell renal carcinoma.
  • Although chemotherapy was given, the patient died of disseminated ovarian cancer metastasis 20 months after operation.
  • In conclusion, coexistence of RCC and ovarian cancer is rare and the pathogenesis remains to be clarified.


5. Pan ZZ, Wan DS, Lu ZH, Li LR, Chen G, Zhou ZW, Wu XJ, Ding PR, Wang FL: [Comparing the effect of adjuvant chemotherapy by portal vein infusion with intraluminal chemotherapy for colorectal cancer]. Zhonghua Wai Ke Za Zhi; 2004 Aug 7;42(15):918-21
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparing the effect of adjuvant chemotherapy by portal vein infusion with intraluminal chemotherapy for colorectal cancer].
  • OBJECTIVE: To compare the effect of 5-fluorouracil (5-FU) portal vein infusion (PVI) for 7 days after radical resection, with intraluminal chemotherapy during operation for eliminating liver metastasis and elevating long-term prognosis in colorectal cancer.
  • METHODS: 162 colorectal cancer patients with radical resection were divided into portal vein chemotherapy group (group A, 82 cases) and intraluminal chemotherapy group (group B, 80 cases) randomly.
  • In group A, 5-fluorouracil were infused with 1g per day constantly for 7 days after operation through portal vein catheters, which placed into greater omental vein and fixed on the abdominal wall.
  • In group B, intraluminal chemotherapy was given and 5-fluorouracil 0.5 g was injected into the greater omental vein during operation.
  • Group A had more operative complications, and no statistical differences was found in hospital time and survival rate of the two groups.
  • The 5-year survival rate is 76.7% (group A: 74.3%, group B: 79.2%), and the liver metastasis rate is 19.8%.
  • CONCLUSIONS: The present study demonstrated that the two chemotherapy methods play an important role in preventing liver metastasis and improving the survival rate, and the intraluminal chemotherapy would be easier and simpler.
  • The result should be further improved by using combined chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Colorectal Neoplasms / drug therapy. Fluorouracil / administration & dosage
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Portal Vein. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15363253.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Trautmann TG, Zuger JH: Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol; 2005 Jul-Aug;7(4):309-13
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron Emission Tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal.
  • PURPOSE: In recent years, combined modality therapy (CMT) with chemotherapy and radiation has replaced surgery as the preferred treatment for cancer of the anal canal.
  • Clinical staging with computed tomography (CT) scan alone may underestimate the extent of disease.
  • We investigated the utility of positron emission tomography (PET) with 2-deoxy-2[F-18]fluoro-D-glucose (FDG) in the staging and determination of response to CMT.
  • PATIENTS AND METHODS: From September 1999 to August 2002, 21 patients with cancer of the anal canal were studied prospectively.
  • These sites included pelvic lymph nodes (four patients) and distant omental metastasis (one patient).
  • Nine patients had minimal residual PET activity at the primary site on the one-month follow-up PET study, but only three of these subsequently developed local recurrence.
  • CONCLUSIONS: FDG-PET, in conjunction with CT scanning, provides additional staging information in cancer of the anal canal.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / diagnosis. Anus Neoplasms / pathology. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / diagnosis. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1999 Feb;70(2):71-7 [10084647.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):880-914 [11704310.001]
  • [Cites] Cancer Treat Rev. 2004 Feb;30(1):83-101 [14766127.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1034-9 [15020605.001]
  • [Cites] Eur J Nucl Med. 2000 May;27(5):590-4 [10853816.001]
  • [Cites] J Nucl Med. 1992 Nov;33(11):1972-80 [1432158.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):853-63 [14529793.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Ann Surg Oncol. 1997 Dec;4(8):613-20 [9416407.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):41-5 [10458216.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3995-4000 [14581422.001]
  • (PMID = 16028002.001).
  • [ISSN] 1536-1632
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Zagouri F, Papaefthimiou M, Chalazonitis AN, Antoniou N, Dimopoulos MA, Bamias A: Prostate cancer with metastasis to the omentum and massive ascites: a rare manifestation of a common disease. Onkologie; 2009 Dec;32(12):758-61
MedlinePlus Health Information. consumer health - Rare Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer with metastasis to the omentum and massive ascites: a rare manifestation of a common disease.
  • BACKGROUND: The most common sites of metastasis in prostate cancer include bone and regional lymph nodes followed by lung, liver, and brain.
  • Peritoneal metastasis without skeletal involvement is extremely rare.
  • CASE REPORT: We present herein a patient with hormone refractory prostate cancer with peritoneal metastasis accompanied by ascites but without bone metastasis.
  • The patient initially experienced an excellent response to docetaxel-based chemotherapy.
  • CONCLUSIONS: Prostate cancer can present with distant metastasis in unexpected sites.
  • The presence of ascites may indicate peritoneal disease which could be responsive to current standard chemotherapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Ascites / diagnosis. Omentum / pathology. Peritoneal Neoplasms / secondary. Prostatic Neoplasms / pathology. Rare Diseases / diagnosis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 20016239.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


8. Ferrandina G, Stoler A, Fagotti A, Fanfani F, Sacco R, De Pasqua A, Mancuso S, Scambia G: p21WAF1/CIP1 protein expression in primary ovarian cancer. Int J Oncol; 2000 Dec;17(6):1231-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p21WAF1/CIP1 protein expression in primary ovarian cancer.
  • p21WAF1/CIP1 protein is a cyclin-dependent kinase inhibitor, able to prevent the CDK2/cyclin E induced retinoblastoma protein (pRB) phosphorylation, thus inhibiting cell cycle progression at G1 phase. p21WAF1/CIP1 protein levels were examined in a series of 102 ovarian tissue samples including normal ovary, primary ovarian tumors, omental metastasis, recurrent disease and residual tumor after chemotherapy exposure, by Western blot analysis.
  • The association of p21WAF1/CIP1 status with clinicopathological parameters and clinical outcome was also investigated. p21WAF1/CIP1 protein was detectable in 76 out of 102 (74%) ovarian tissue samples.
  • We observed a significant trend of p21 levels to gradually increase from normal ovarian tissues (median 0 a.u.) through primary ovarian cancers (median 0.19 a.u.
  • ), omental metastases (median 0.33 a.u.) and recurrence of disease (median 0.44 a.u. ) (p=0.015).
  • In the group of stage III-IV ovarian cancer patients, p21-positive cases showed a more favourable prognosis with respect to p21-negative cases: the 3-year time to progression (TTP) rate was 58% for p21-positive compared with 33% of p21-negative cases (p=0.036).
  • In conclusion, p21WAF1/CIP1 expression levels seem to be correlated with tumor status at the time of diagnosis and can predict TTP in a selected group of patients.
  • [MeSH-major] Cyclins / biosynthesis. Cystadenocarcinoma, Serous / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / secondary. Carcinoma, Endometrioid / surgery. Cell Cycle. Cisplatin / administration & dosage. Cyclin-Dependent Kinase Inhibitor p21. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / genetics. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / secondary. Cystadenocarcinoma, Mucinous / surgery. Disease Progression. Female. Genes, p53. Humans. Life Tables. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neoplasm, Residual. Omentum. Ovary / metabolism. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11078810.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Neoplasm Proteins; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Ayhan A, Taskiran C, Yigit-Celik N, Bozdag G, Gultekin M, Usubutun A, Guler N, Yuce K: Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer? Int J Gynecol Cancer; 2006 Mar-Apr;16(2):484-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?
  • The purpose of this study was to compare the effect of paclitaxel plus platinum-based chemotherapy in the treatment of extraovarian peritoneal serous papillary carcinoma (EPSPC) and ovarian serous papillary cancer (OSPC).
  • Only the patients treated with initial surgery plus postoperative adjuvant chemotherapy and having FIGO stage IIIC disease with omental and/or peritoneal involvement were analyzed.
  • As an adjuvant therapy, the paclitaxel plus platinum-based combination regimen had similar effects on survival in the EPSPC and OSPC groups.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Papillary / drug therapy. Cystadenocarcinoma, Serous / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Female. Humans. Lymphatic Metastasis / pathology. Middle Aged. Paclitaxel / administration & dosage. Retrospective Studies. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681715.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Shibaki T, Morimoto N: [Advanced rectal cancer in an older patient, in whom metastatic liver lesions were effectively controlled with oral UFT+LV and venous CPT-11 administration--case report]. Gan To Kagaku Ryoho; 2006 Jun;33(6):825-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced rectal cancer in an older patient, in whom metastatic liver lesions were effectively controlled with oral UFT+LV and venous CPT-11 administration--case report].
  • He was diagnosed with sigmoid colon cancer with multiple metastatic lesions in the right lobe of the liver.
  • The final diagnosis was stage IV sigmoid colon cancer with metastasis to the omentum.
  • One month after the operation, adjuvant chemotherapy with oral administration of tegafur/uracil compound (UFT) and Leucovorin (LV), and drip venous infusion of irinotecan hydrochloride (CPT-11) was initiated (UFT 300 mg/day for 14 days, LV 75 mg/day for 14 days, CPT-11 90 mg/m(2) on the 1 st day, with 1 course consisting of 21 days).
  • The levels of tumor markers, CA19-9 and CEA, and the size of metastases on CT were reduced remarkably after one and 4 courses of this therapy, respectively.
  • Although the administration was temporarily discontinued due to low-grade nausea, we continued the treatment.
  • Adjuvant chemotherapy with an oral administering agent is favorable for older patients with advanced colorectal cancer to reduce side effects and preserve the quality of life.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged, 80 and over. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Colon, Sigmoid / surgery. Colostomy. Drug Administration Schedule. Drug Combinations. Humans. Infusions, Intra-Arterial. Leucovorin / administration & dosage. Male. Omentum / pathology. Peritoneal Neoplasms / secondary. Remission Induction. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770106.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


11. Anfinan NM, Sait KH, Al-Maghrabi JA: Primitive neuroectodermal tumor of the ovary. Saudi Med J; 2008 Mar;29(3):444-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exploratory laparotomy showed huge right ovarian mass with omental mass.
  • Frozen section from the omentum showed metastatic malignant neoplasm.
  • She received post- operative chemotherapy.
  • Four months later she had recurrence and was given second line chemotherapy, but she did not respond and died 15 months after the diagnosis due to obstructive uropathy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18327377.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


12. Takeuchi N, Nakai M, Sato M: [A case of omental mesothelioma presenting with laminar thickening of omentum-appearances of diffuse malignant peritoneal mesothelioma]. Gan To Kagaku Ryoho; 2008 Apr;35(4):677-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of omental mesothelioma presenting with laminar thickening of omentum-appearances of diffuse malignant peritoneal mesothelioma].
  • A man in his 60's with no apparent history of asbestos exposure was admitted to our hospital with a chief complaint of abdominal fullness.
  • Enhanced abdominal CT confirmed a large amount of ascites, inflexible intestinal canal, short mesentery and laminar thickening of the omentum.
  • SPIO-enhanced MRI-T1WI slightly enhanced the thickened omentum.
  • Furthermore, the thickened omentum was clearly visualized by lowering the signal for the liver and spleen by SPIO and by suppressing the ascites signal by fluid-attenuated inversion recovery (FLAIR).
  • Chemotherapy was ineffective, and the patient died of liver metastasis in February 2006.
  • Autopsy confirmed biphasic malignant peritoneal mesothelioma.
  • The involvement of asbestos is clear in the onset of malignant peritoneal mesothelioma.
  • Hence, when levels of CA125 in serum and/or ascites are high, it is important to differentiate malignant peritoneal mesothelioma from primaryserous papillary carcinoma of the peritoneum.
  • Here, we experienced a case of biphasic diffused omental mesothelioma.
  • While studies have documented laminar thickening of the omentum by abdominal incision, this is thought to be first case in Japan in which laminar thickening of the omentum was detected on diagnostic imaging.
  • Laminar thickening of the omentum and short mesentery are thought to be characteristic features of diffused peritoneal mesothelioma when subjective symptoms appear.
  • In the future, we hope to differentiate epithelial, sarcomatous and biphasic types based on imaging findings.
  • [MeSH-major] Mesothelioma / pathology. Mesothelioma / radiography. Omentum / pathology. Omentum / radiography
  • [MeSH-minor] Aged. Diffusion. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radionuclide Imaging. Tomography, X-Ray Computed. Treatment Failure

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408444.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Duhan N, Singh S, Kadian YS, Duhan U, Rajotia N, Sangwan N: Primary leiomyosarcoma of broad ligament: case report and review of literature. Arch Gynecol Obstet; 2009 May;279(5):705-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Primary leiomyosarcoma of the broad ligament (LBL) is a very rare and highly malignant gynecological tumor.
  • Treatment consisted of resection of the tumor along with omental and peritoneal sampling and adjuvant chemotherapy.
  • No evidence of metastasis was present after 15 months of follow up.
  • CONCLUSION: Complete surgery along with adjuvant chemotherapy or radiation and a close follow up for recurrence are advocated to optimize disease free survival.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18777035.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 27
  •  go-up   go-down


14. Garofalo A, Valle M: Laparoscopy in the management of peritoneal carcinomatosis. Cancer J; 2009 May-Jun;15(3):190-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy in the management of peritoneal carcinomatosis.
  • The use of videolaparoscopy in the assessment of peritoneal carcinomatosis extent is now universally accepted.
  • This procedure allows us to define with certainty the origin of the neoplasm, the peritoneal cancer index (PCI), the involvement of the small bowel and its mesentery, the feasibility of surgery and the index of attainable cytoreduction, the evaluation of an eventual multiorgan resection, and finally results in no mortality and very low morbidity.The indications for laparoscopy are as follows: staging of the carcinomatosis already diagnosed with imaging (CT scan and MRI), staging of carcinomatosis of dubious origin (biopsy), restaging after neoadjuvant chemotherapy, restaging during follow-up in the case of dubious imaging, and restaging after adjuvant chemotherapy.Open (Hasson) technique has always been used in the introduction of the first trocar, and the changing position of the surgical bed allows for the evaluation of all the abdominal quadrants, limiting viscerolysis to the essential minimum to avoid iatrogenic lesions.
  • Associating the intraoperative ultrasound has allowed us to reduce understaging of lesions at the depth of the diaphragm, of hepatic metastases and neoplastic masses at the pancreatic tail, and of the omental retrocavity.In all the cases in which diagnostic laparoscopy was followed by peritonectomy, we found a good correlation between open surgery data and the laparoscopic PCI.
  • We excluded patients from peritonectomy if the staging laparoscopy showed a significant involvement of the small bowel or mesentery.We used videolaparoscopy to stage 197 cases of peritoneal carcinomatosis and achieved full laparoscopic PCI assessment in 196 of 197 (99.49%) cases, whereas only 4 of 197 (2.03%) cases were understaged before the routine use of laparoscopic ultrasound.
  • Four complications were observed: 2 cases (1.02%) involved an infection of the trocar insertion site, which was treated with antibiotic therapy, and 2 cases (1.02%) involved diaphragm perforation and intraoperative bleeding, respectively, both resolved with videolaparoscopic technique.
  • There was no mortality and no port site metastasis.More recently, we have used videolaparoscopic surgery in the treatment of neoplastic ascites that did not respond to chemotherapy for palliative purposes, which resulted in the total disappearance of the ascites.
  • In 28 cases of neoplastic ascites nonrespondent to chemotherapy, we were able to implement fully laparoscopic hyperthermic chemotherapy for the palliative treatment of the ascites, with total disappearance of it in all cases.
  • The l-hyperthermic intraperineal chemotherapy was carried out at 42 degrees C for 90 minutes with 1.5% dextrose solution as a carrier.
  • The chemotherapy solution was cisplatin and doxorubicin, or mitomycin, depending on the type of primary tumor.
  • A computed tomography scan performed in follow-up showed a small, clinically undetectable, fluid accumulation in the pelvis of 1 patient.
  • Neither mortality nor morbidity was observed in connection with the procedure.
  • [MeSH-major] Laparoscopy. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Male. Neoplasm Staging / methods. Treatment Outcome. Video Recording

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19556903.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Park JY, Lee S, Kang HJ, Kim HS, Park SY: Primary Ewing's sarcoma-primitive neuroectodermal tumor of the uterus: a case report and literature review. Gynecol Oncol; 2007 Aug;106(2):427-32
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A computed tomography (CT) scan and magnetic resonance imaging (MRI) of the abdomen and pelvis showed a huge uterine mass measuring 18 x 20 x 21 cm, metastasis to both pelvic and para-aortic lymph nodes, and omental infiltration.
  • The patient received several courses of combination chemotherapy and radiotherapy but died from tumor progression 16 months after the initial diagnosis.
  • A review of the literature indicates that primary uterine ES-PNET requires early diagnosis and multimodality treatment including surgery, chemotherapy, and radiotherapy.

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572479.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kato T, Sato K, Tamahashi N, Yano H, Masuoka HO: [A case of small cell carcinoma of the stomach]. Gan To Kagaku Ryoho; 2005 Oct;32(10):1473-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a rare case of small cell carcinoma of the stomach with metastasis to the liver and invasion of the pancreas, which was associated with acute peritonitis due to perforation of the stomach.
  • CPT-11/CDDP chemotherapy achieved a partial response.
  • A 60-year-old man suddenly developed abdominal pain and visited the emergency room.
  • An emergency operation was performed with an omental patch for closing the perforated hole in the stomach.
  • Histological findings showed that the liver nodule was metastasis from small cell carcinoma.
  • Therefore, we diagnosed small cell carcinoma of the stomach with liver metastasis and invasion of the pancreas.
  • After operation, one course of FP chemotherapy was performed, but the liver metastasis increased in size.
  • Then we changed to CPT-11/CDDP chemotherapy as second-line therapy, and achieved partial remission (PR) of both the liver metastasis and gastric tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Gastrectomy. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Invasiveness. Pancreatic Neoplasms / pathology. Rupture, Spontaneous. Stomach Rupture / etiology

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227752.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


17. Koga T, Kusumoto T, Kakeji Y, Kishikawa K, Maehara Y, Yonemura T, Irie K, Sugimachi K: Leiomyosarcoma of the greater omentum with liver metastasis: report of a case. Surg Today; 2002;32(5):434-8
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of the greater omentum with liver metastasis: report of a case.
  • We report herein a rare case of leiomyosarcoma arising from the greater omentum with concomitant liver metastases.
  • The findings of several examinations led us to suspect an omental leiomyosarcoma.
  • A laparotomy revealed an elastic hard and foliaceous mass (12.5 x 9.0 x 8.0 cm) arising from the omentum, and six masses in the liver.
  • The omental tumor was extirpated and chemotherapy was administered under the guidance of angiography.
  • The final diagnosis was leiomyosarcoma of the omentum.
  • About 9 months after the operation, multiple liver metastases were found and repeated chemotherapy was given, but without effect.
  • A partial hepatectomy was done, accompanied by microwave coagulation therapy (MCT).
  • [MeSH-major] Leiomyosarcoma / secondary. Liver Neoplasms / secondary. Omentum. Peritoneal Neoplasms / pathology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12061696.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 31
  •  go-up   go-down


18. Fujisaki S, Takashina M, Tomita R, Sakurai K, Takayama T: [A case of perforated advanced gastric carcinoma accompanied with single liver metastases, who underwent total gastrectomy and hepatectomy of caudate lobe after drainage operation of peritonitis]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2448-50
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was diagnosed as a gastric perforation and peritonitis due to a suspected gastric cancer.
  • He underwent omental implantation and peritoneal drainage for peritonitis.
  • After the surgery, a liver metastasis was found on the findings of the enhanced abdominal CT scan.
  • Eighteen days after the curative surgery, he started to receive postoperative adjuvant chemotherapy.
  • He has been well without recurrence for 2 years and half following the start of chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Peritonitis / etiology. Peritonitis / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224602.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Nur-Syahrina R, Siti-Aishah MA, Swaminathan M, Ng PH, Ismail S, Syazarina SO, Aini AA, Das S: An unexpected case of primary peritoneal carcinoma. Clin Ter; 2010;161(3):261-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unexpected case of primary peritoneal carcinoma.
  • Primary peritoneal carcinoma (PPC) is a rare tumor that is histologically and immunohistochemically indistinguishable from epithelial ovarian carcinoma.
  • The diagnosis is usually made after excluding gross ovarian involvement or the ovarian involvement is only confined to the surface.
  • The CT scan showed bilateral pelvic adnexal masses with peritoneal deposits within the right side of abdomen.
  • She was initially diagnosed as carcinomatosis peritonei from the omental cake removed after exploratory surgery.
  • She was managed as advanced ovarian tumor with peritoneal metastasis and was then administered six cycles of chemotherapy.
  • The histopathological findings were of primary peritoneal serous carcinoma with only minimal involvement of the serosal surface of the right ovarian capsule.
  • Multiple tumor deposits were also seen over the right paratubal and paraovarian tissue, both parametrium as well as serosal surface of the terminal ileum and periappendicular tissue.
  • Immunohistochemically, the malignant cells were positive to CA125, focally positive to CK7 and negative to CD20 and Calretinin.
  • PPC is one of important differential diagnosis which needs to be considered in cases of advanced ovarian tumor, although the former can only be ascertained after excluding the ovarian involvement microscopically.
  • [MeSH-major] Carcinoma / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20589359.001).
  • [ISSN] 1972-6007
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Alkhamesi NA, Ziprin P, Pfistermuller K, Peck DH, Darzi AW: ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention. Clin Exp Metastasis; 2005;22(6):449-59
Hazardous Substances Data Bank. HEPARIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention.
  • Development of peritoneal metastasis is a significant issue in the treatment of abdominal cancers.
  • Our aim was to determine the role of the intercellular adhesion molecule-1 (ICAM-1) in mesothelial-tumour adhesion and the effectiveness of therapeutic intervention.
  • Mesothelial cells were derived from omental tissue.
  • These data imply that heparin may be used as a potential therapeutic through a defined molecular mechanism both in vitro and in vivo.
  • Hyaluronan appears to function as a barrier and hence may be unreliable in blocking peritoneal recurrence.
  • [MeSH-major] Carcinoma / drug therapy. Cell Adhesion / drug effects. Heparin / therapeutic use. Intercellular Adhesion Molecule-1 / metabolism. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Down-Regulation. Epithelium / drug effects. Epithelium / metabolism. Epithelium / pathology. Flow Cytometry. Humans. Hyaluronic Acid / pharmacology. Hyaluronic Acid / therapeutic use. Rats. Tumor Necrosis Factor-alpha / pharmacology

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1999 Apr;188(4):421-6 [10195727.001]
  • [Cites] Oncol Rep. 2004 Oct;12 (4):683-8 [15375485.001]
  • [Cites] Arch Surg. 1998 Jun;133(6):652-6 [9637466.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):593-9 [10100711.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3830-8 [8339295.001]
  • [Cites] Pharmacol Rev. 2001 Mar;53(1):93-105 [11171940.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1944-8 [15143088.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):246-50 [11167875.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1228-32 [9102203.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):242-8 [9488523.001]
  • [Cites] Cancer Treat Rev. 2002 Jun;28(3):151-5 [12234567.001]
  • [Cites] Br J Surg. 2003 Jan;90(1):66-71 [12520577.001]
  • [Cites] Cell Commun Adhes. 2003 May-Jun;10(3):141-54 [14668061.001]
  • [Cites] Br J Surg. 1996 Mar;83(3):347-8 [8665188.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4427-34 [10485493.001]
  • [Cites] Kidney Int. 1990 Jun;37(6):1563-70 [2362409.001]
  • [Cites] Cell Adhes Commun. 1997 Mar;4(6):439-55 [9177905.001]
  • [Cites] Surgery. 1987 Jul;102(1):71-8 [3495896.001]
  • [Cites] Ann Surg. 1978 Dec;188(6):711-5 [736648.001]
  • [Cites] Clin Exp Metastasis. 1990 Mar-Apr;8(2):165-71 [2317956.001]
  • [Cites] Thromb Haemost. 2004 Sep;92 (3):627-33 [15351861.001]
  • [Cites] J Mol Med (Berl). 1996 Jan;74(1):13-33 [8834767.001]
  • [Cites] J Cell Sci. 1999 Jul;112 ( Pt 13):2241-51 [10362554.001]
  • [Cites] Eur J Histochem. 2003;47(1):63-73 [12685559.001]
  • [Cites] Oncol Res. 2002;13(2):71-8 [12392154.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1A):293-9 [9066667.001]
  • [Cites] Surg Endosc. 1996 Aug;10(8):809-12 [8694943.001]
  • [Cites] Thromb Haemost. 1998 Sep;80(3):481-7 [9759631.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1134-40 [9749497.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1294-8 [9369102.001]
  • [Cites] Dis Colon Rectum. 2002 Mar;45(3):334-41; discussion 341-4 [12068190.001]
  • [Cites] Surg Endosc. 2001 May;15(5):504-7 [11353970.001]
  • [Cites] Surg Endosc. 2001 Jan;15(1):59-62 [11178765.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1138-50 [1904477.001]
  • [Cites] Clin Exp Metastasis. 1998 Nov;16(8):703-12 [10211983.001]
  • [Cites] World J Surg. 1996 Jun;20(5):585-91; discussion 592 [8661635.001]
  • [Cites] Biol Chem. 2004 Aug;385(8):755-61 [15449712.001]
  • [Cites] Invasion Metastasis. 1994-1995;14(1-6):290-302 [7657522.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1525-37 [10329605.001]
  • [Cites] J Immunol. 1998 Mar 15;160(6):2967-73 [9510201.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):400-4 [10201788.001]
  • (PMID = 16320108.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 126547-89-5 / Intercellular Adhesion Molecule-1; 9004-61-9 / Hyaluronic Acid; 9005-49-6 / Heparin
  •  go-up   go-down


21. Khalifeh I, Deavers MT, Cristofanilli M, Coleman RL, Malpica A, Gilcrease MZ: Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. Breast J; 2009 Mar-Apr;15(2):176-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peritoneal serous carcinoma presenting as inflammatory breast cancer.
  • Metastasis to the breast from extramammary malignancies is rare.
  • Nevertheless, its recognition is important because the prognosis and treatment differ from that of primary breast cancer.
  • We report a unique case of primary peritoneal serous carcinoma that initially presented as inflammatory breast cancer.
  • The patient received neoadjuvant chemotherapy for breast cancer and subsequently underwent bilateral total mastectomy and bilateral sentinel lymph node biopsy.
  • She was found to have extensive intralymphatic carcinoma in both breasts, with only focal minimal breast parenchymal involvement, and residual metastatic carcinoma in bilateral sentinel lymph nodes.
  • Further work-up revealed pelvic ascites and omental nodularities.
  • To our knowledge, this is the first reported case of an extramammary primary malignancy that not only presented as inflammatory breast cancer but also was diagnosed and initially treated as such.
  • [MeSH-major] Breast Neoplasms / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Diagnosis, Differential. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Inflammation / pathology. Magnetic Resonance Imaging. Mastectomy. Middle Aged. Neoplasm Metastasis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovariectomy. Sentinel Lymph Node Biopsy


22. Vergote I, Marquette S, Amant F, Berteloot P, Neven P: Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. Int J Gynecol Cancer; 2005 Sep-Oct;15(5):776-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Open laparoscopy was used to diagnose advanced ovarian cancer.
  • Patients with a pelvic mass and an omental cake and/or large-volume ascites were selected for open laparoscopy.
  • Seventy-one patients underwent complete excision of port sites at the time of debulking surgery.
  • Thirty (17%) patients developed port-site metastases.
  • There was no significant relationship between the development of port-site metastases and median time to primary chemotherapy or surgery, the presence of ascites, or stage IV disease.
  • All port-site metastases disappeared during primary therapy, and none of the patients developed a second relapse in one of their port sites.
  • [MeSH-major] Laparoscopy / adverse effects. Neoplasm Metastasis / pathology. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174223.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Schorge JO: Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol; 2004 Aug;104(2):261-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical staging of ovarian low malignant potential tumors.
  • OBJECTIVE: Women diagnosed with ovarian tumors of low malignant potential have an excellent prognosis.
  • Because few will receive adjuvant therapy, the benefit of surgical staging has recently been challenged.
  • The purpose of this study was to compare the outcome of surgically staged patients with low malignant potential tumors with those who were not staged.
  • METHODS: Between 1984 and 2003, all women with ovarian low malignant potential tumors were identified at 3 institutions.
  • Cytologic washings were positive in 28 cases, 10 had microscopic implants detected by peritoneal or omental biopsy, and 2 were upstaged to stage IIIC solely on the basis of nodal metastases.
  • Eight (3%) of 248 patients received adjuvant platinum-based chemotherapy, but neither of the women upstaged to IIIC based on the results of their nodal dissection were treated.
  • Fifteen (6%) recurrences developed and 1 (0.4%) death occurred after a median follow-up of 28 (range, 1-208) months.
  • CONCLUSION: Routine pelvic and para-aortic lymph node dissection is not necessary in the majority of women with ovarian low malignant potential tumors.
  • [MeSH-major] Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Massachusetts / epidemiology. Medical Records. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. North Carolina / epidemiology. Retrospective Studies. Texas / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15291997.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Oku T, Waga E, Sumiyoshi T, Yoshizaki N, Kondo H, Ohira N, Takayama T, Shikishima H, Motohara T: [A case of primary small intestinal gastrointestinal stromal tumor: an intraperitoneal bleeding from greater omentum metastasis caused by administration of imatinib mesylate]. Nihon Shokakibyo Gakkai Zasshi; 2003 Jul;100(7):863-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary small intestinal gastrointestinal stromal tumor: an intraperitoneal bleeding from greater omentum metastasis caused by administration of imatinib mesylate].
  • [MeSH-major] Antineoplastic Agents / adverse effects. Gastrointestinal Neoplasms / drug therapy. Hemorrhage / etiology. Intestine, Small. Peritoneal Diseases / etiology. Peritoneal Neoplasms / secondary. Piperazines / adverse effects. Pyrimidines / adverse effects
  • [MeSH-minor] Aged. Benzamides. Humans. Imatinib Mesylate. Male. Omentum. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12884763.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down






Advertisement